Atlas Trials

A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

Clinical trial NCT02954406 · TERMINATED

Trial details

NCT number
NCT02954406
Sponsor
Millennium Pharmaceuticals, Inc.
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Lymphoma, Non-Hodgkin
Start date
2017-03-05
Primary completion
2020-07-27
Enrollment
43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.